U.S. Markets close in 4 hrs 26 mins
  • S&P 500

    4,479.51
    +8.14 (+0.18%)
     
  • Dow 30

    35,279.74
    -15.02 (-0.04%)
     
  • Nasdaq

    14,945.89
    +48.55 (+0.33%)
     
  • Russell 2000

    2,264.91
    -0.74 (-0.03%)
     
  • Gold

    1,768.70
    +0.40 (+0.02%)
     
  • EUR/USD

    1.1608
    +0.0007 (+0.0580%)
     
  • 10-Yr Bond

    1.6000
    +0.0810 (+5.33%)
     
  • Vix

    16.55
    +0.25 (+1.53%)
     
  • GBP/USD

    1.3719
    +0.0042 (+0.3101%)
     
  • USD/JPY

    114.2500
    +0.5730 (+0.5041%)
     
  • BTC-USD

    61,837.78
    +973.70 (+1.60%)
     
  • CMC Crypto 200

    1,441.47
    -10.17 (-0.70%)
     
  • FTSE 100

    7,204.08
    -29.95 (-0.41%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., September 01, 2021--(BUSINESS WIRE)--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference, being held virtually on September 10, 2021, at 11:45am ET.

A live webcast of the fireside chat will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005062/en/

Contacts

INVESTOR CONTACT:
Lisa Hayes
Vice President, Investor Relations and Corporate Communications
908-868-8926
Lisa.Hayes@cyteir.com

MEDIA CONTACT:
Michele Parisi
925-429-1850
mparisi@forwardhealthinc.com